
Epcoritamab shows high response rates in elderly diffuse large B-cell lymphoma patients in new trials.
Genmab announced positive Phase 2 and Phase 1b/2 trial results for epcoritamab, a T-cell engaging antibody, in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who are ineligible for standard chemotherapy. The Phase 2 trial...

